Lose Up to 14%+ of Your Body Weight With the Wegovy® Pill — No Needles Required

Prescription products require an online evaluation with a licensed medical professional who will determine if a prescription is appropriate. See important safety information. Benefits outlined on Get Thin MD are based on 3rd party studies. Medications are prescribed by licensed physicians as part of our weight loss programs. Actual product packaging may appear differently than shown. Physicians may prescribe compounded medications as needed to meet patient requirements or drug shortages. The FDA does not review or approve any compounded medications for safety or effectiveness.

Should you seek a prescription item, Get Thin MD will facilitate arranging a consultation with a qualified Healthcare Provider. The Provider will assess your suitability for the prescription item. If deemed suitable, a doctor may issue a prescription for the item, which can be filled at a partner pharmacy, unless you specify an alternative preference.

As part of our efforts to ensure patient safety, we need to verify your phone number. By giving us your phone number and continuing, you agree that Get Thin MD  may send text messages to you to verify your phone number and for any other lawful purpose related to your Get Thin MD account and your use of our services, including order confirmations, shipment notifications, and messages from your provider. Message and data rates may apply. Message frequency varies. Additionally, by providing your phone number, you agree to receive marketing emails and other promotional communications from Get Thin MD. You also consent to Get Thin MD using your information for third-party advertising purposes, including but not limited to targeted advertising on platforms such as Facebook, Google, and other similar sites. This includes using hashed and de-identified data to create custom audiences for targeted advertising and to exclude existing customers from certain marketing campaigns. You can opt-out of receiving marketing emails at any time by following the unsubscribe instructions provided in each email or by contacting us directly at support@getthinusa.com.
‍
Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
The FDA does not review. compounded medications for safety or efficacy. GetThinMD does not manufacture or dispense medications. GetThinMD connects patients with licensed healthcare providers who may prescribe treatments based on individual eligibility. This product is available by prescription only. Individual results may vary. Bottle used for visual purposes only. Safety information may be found at https://www.getthinusa.com/important-safety-information

¹ Wegovy® (semaglutide) is a prescription medication manufactured by Novo Nordisk and is available in two FDA-approved forms: Wegovy® injection (once-weekly semaglutide 2.4 mg pen), originally approved by the U.S. Food and Drug Administration in June 2021, and Wegovy® Pill (once-daily oral semaglutide 25 mg), approved by the FDA on December 22, 2025 as the first and only oral GLP-1 receptor agonist indicated for chronic weight management in adults with obesity, or adults with overweight who have at least one weight-related medical condition. Get Thin MD is an independent telehealth platform and is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Wegovy® is a registered trademark of Novo Nordisk A/S. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html

² https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

³ Based on data from the OASIS 4 phase 3 clinical trial, 28% of adults taking Wegovy® Pill (oral semaglutide 25 mg) lost 20% or more of their body weight, compared with 3% of adults taking placebo. Average starting weight was 235 lbs for the Wegovy® Pill group and 231 lbs for the placebo group. The 64-week study included 307 adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related medical condition such as high blood pressure or high cholesterol; adults with type 2 diabetes were excluded. All participants followed a reduced-calorie diet and increased physical activity throughout the study. Comparable results have been demonstrated in clinical trials of Wegovy® injection. Get Thin MD does not guarantee that your results will match those of patients represented in these clinical trials. Individual weight loss outcomes may vary based on numerous personal factors.https://www.wegovy.com/obesity/is-wegovy-right-for-me/wegovy-pill-results.html

⁴ Available dosages — 1.5 mg, 4 mg, 9 mg, and 25 mg strengths. Available dosages — is available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg dosages. Dosing is determined by a licensed medical provider based on the patient's individual health profile, treatment response, and tolerability. Not all dosages may be appropriate for every patient. https://www.endocrinologyadvisor.com/news/fda-approves-oral-wegovy-for-weight-management/

⁵ Wegovy® injection (once-weekly semaglutide 2.4 mg) was originally approved by the U.S. Food and Drug Administration in June 2021 for chronic weight management in adults. As of 2025, Wegovy® has been prescribed for approximately 3.2 million people in the United States. Wegovy® injection requires refrigerated storage prior to first use, per the manufacturer's prescribing information. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html